RHYTHM PHARMACEUTICALS INC (RYTM)

Sector: Health Care

    Home/Companies/RYTM/Annual Meeting

2026 Annual Meeting Analysis

RHYTHM PHARMACEUTICALS INC · Meeting: June 24, 2026

Policy v1.2high confidenceView Filing ↗
For informational purposes only. This AI-generated analysis applies a published voting policy to publicly available proxy filings. It does not constitute investment advice, proxy voting advice, or a solicitation of any kind. AI analysis may be incomplete or inaccurate — always review the actual filing and make your own independent decision.

Directors FOR

2

Directors AGAINST

0

Say on Pay

FOR

Auditor

FOR

Director Elections

Election of Directors — Class III Directors David W.J. McGirr and David P. Meeker, M.D.

2 FOR
✓ FOR
David W.J. McGirr

McGirr has served since 2015 and RYTM's 3-year stock return of +288% far outpaces the peer group median of +30% by +258 percentage points, well above the 65-point threshold required to trigger an against vote; no overboarding, attendance, or independence concerns are present.

✓ FOR
David P. Meeker, M.D.

As CEO-director since 2015, Meeker oversaw a 3-year stock return of +288% versus the peer group median of +30%, an outperformance of +258 percentage points that far exceeds the 65-point trigger threshold; he holds two outside chairmanships but is not a sitting CEO at another public company, so no overboarding rule is triggered.

Both Class III director nominees pass all policy screens: RYTM's exceptional 3-year stock outperformance (+258pp above peer group median, versus a 65pp trigger threshold) means the TSR trigger does not apply, no attendance problems are disclosed, all independence designations appear appropriate, and neither director is overboarded under our policy.

Say on Pay

✓ FOR

CEO

David P. Meeker

Total Comp

$17,544,525

Prior Support

69.4%%

prior say on pay below 70 percentmeaningful shareholder engagement response

The prior year Say on Pay vote came in at 69.4%, which is below the 70% threshold that normally requires the company to make visible changes — however, Rhythm responded substantively by conducting proactive outreach to holders representing over 50% of shares, enhancing compensation disclosure throughout the proxy, committing to 100% corporate-goal-based CEO bonuses starting in 2026, and publicly acknowledging stockholder concerns about performance-based equity; these are meaningful, concrete changes rather than empty promises. CEO total pay of approximately $17.5 million is high in absolute terms, but roughly 95% is delivered as long-term equity tied to stock price, and RYTM's 3-year total shareholder return of +288% is in the 84th percentile of its peer group while CEO realizable pay is positioned at the 79th percentile — a clear pay-for-performance alignment. The pay mix is overwhelmingly variable and performance-sensitive (approximately 91% at-risk), a clawback policy compliant with Nasdaq rules is in place, and the company's stock outperformance strongly justifies above-median incentive compensation, making a FOR determination appropriate despite the prior-year flag.

Auditor Ratification

✓ FOR

Auditor

Ernst & Young LLP

Tenure

N/A

Audit Fees

$2,188,982

Non-Audit Fees

$147,853

Non-audit fees (tax services of $147,853) represent only about 6.8% of audit fees ($2,188,982), well below the 50% threshold that would raise independence concerns; no material restatements are disclosed, and Ernst & Young is a Big 4 firm appropriate for a company of RYTM's size; auditor tenure is not disclosed in the filing, so the tenure trigger cannot fire and we default to FOR per policy.

Overall Assessment

The 2026 Rhythm Pharmaceuticals annual meeting presents three standard proposals: two Class III director nominees who benefit from exceptional 3-year stock outperformance, an auditor ratification with a clean fee profile, and a Say on Pay vote where the company made genuine and concrete improvements in response to last year's below-70% shareholder support, supported by strong pay-for-performance alignment. All three proposals receive a FOR determination under our policy.

Filing date: April 29, 2026·Policy v1.2·high confidence

Compensation Peer Group

20 companies disclosed in 2026 proxy filing

AGIOAgios Pharmaceuticals
FOLDAmicus Therapeutics
APLSApellis Pharmaceuticals
ARDXArdelyx
BCRXBioCryst Pharmaceuticals
BPMCBlueprint Medicines Corporation
BBIOBridgeBio Pharma, Inc.
CPRXCatalyst Pharmaceuticals, Inc.
INSMInsmed Incorporated
ITCIIntra-Cellular Therapies
IRWDIronwood Pharmaceuticals
KRYSKrystal Biotech, Inc.
MIRMMirum Pharmaceuticals, Inc.
OCULOcular Therapeutix
PTCTPTC Therapeutics, Inc.
SWTXSpringWorks Therapeutics
TGTXTG Therapeutics
TVTXTravere Therapeutics
RAREUltragenyx Pharmaceuticals
VCELVericel Corporation